Skip to main content

Advertisement

Table 1 Characteristics of the 668 included patients

From: The prolonged interval between induction chemotherapy and radiotherapy is associated with poor prognosis in patients with nasopharyngeal carcinoma

Characteristics Interval ≤ 30 days (608 patients) Interval > 30 days (60 patients) P-value
Age (years) 44.5 ± 11.0 44.8 ± 11.2 0.808a
Gender    0.304b
 Male 462 (76.0%) 42 (70.0%)  
 Female 146 (24.0%) 18 (30.0%)  
CCI score    0.088c
 0 519 (85.4%) 56 (93.3%)  
 1 87 (14.3%) 4 (6.7%)  
  ≥ 2 2 (0.3%) 0 (0%)  
T categorye    0.034c
 T1 54 (8.9%) 3 (5.0%)  
 T2 86 (14.1%) 6 (10.0%)  
 T3 299 (49.2%) 27 (45.0%)  
 T4 169 (27.8%) 24 (40.0%)  
N categorye    0.211c
 N0 47 (7.7%) 5 (8.3%)  
 N1 339 (55.8%) 29 (48.3%)  
 N2 101 (16.6%) 7 (11.7%)  
 N3 121 (19.9%) 19 (31.7%)  
Stagee    0.105c
 II 77 (12.7%) 7 (11.7%)  
 III 263 (43.3%) 19 (31.7%)  
 IVa 268 (44.1%) 34 (56.7%)  
EBV DNA (103 copies/ml) 5.6 (0–3290) 6.1 (0–3660) 0.476c
lnDNAf 7.5 ± 4.0 7.8 ± 4.1 0.504a
WHO pathology    0.728d
 I 6 (1.0%) 0 (0%)  
 II 28 (4.6%) 4 (6.7%)  
 III 574 (94.4%) 56 (93.3%)  
IC cycles    <  0.001c
 1 75 (12.3%) 5 (8.3%)  
 2 315 (51.8%) 21 (35.0%)  
 3 187 (30.8%) 18 (30.0%)  
 ≥ 4 31 (5.1%) 16 (26.7%)  
Concurrent chemotherapy    0.028b
 Yes 497 (81.7%) 42 (70.0%)  
 No 111 (18.3%) 18 (30.0%)  
  1. Data presented as number (%), mean ± standard deviation or median (range)
  2. Abbreviations: CCI Charlson comorbidity index, EBV Epstein-Barr virus, IC Induction chemotherapy
  3. aIndependent samples t-test
  4. bPearson chi-square test
  5. cWilcoxon rank-sum test
  6. dFisher’s exact test
  7. eAccording to the 8th edition of AJCC/UICC staging system
  8. flnDNA = ln (EBV DNA × 1000 + 1)